NOXOPHARM-LIMITED
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease. Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
The relevance of blocking TBK1 is seen as important in two respects: (i) ability to block a dysfunctional immune response to RNA viruses such as coronavirus and influenza virus; (ii) potential to avoid the adverse immune-suppressing effects of standard anti-inflammatory drugs such as prednisone and dexamethasone in potentially slowing viral clearance and increasing the risk of secondary infections.
“The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation,” said Noxopharm CEO and Managing Director Graham Kelly . “In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.”
“Based on what is known today, Veyonda’s properties give it the potential to address a gap in our armory of COVID-19 therapeutics,” said Marcel Nold , M.D., professor of pediatric immunology at Monash University and the Hudson Institute and pediatrician at Monash Children’s Hospital. “Patients can self-administer, allowing its use in their own home. Its mechanism of action may enable treatment of moderately ill COVID-19 patients and, importantly, it could also be effective against many other viruses. In Veyonda, Noxopharm has an exciting opportunity at hand.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of Multi-Property Real Estate Portfolio Across Texas10.11.2025 14:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VI, L.P. has successfully completed the sale of three multifamily properties across Texas which were sold to three separate buyers. Financial terms of the transaction were not disclosed. The entire portfolio totaled 606 property units: a 208-unit garden style multifamily community built in 2004 and located in Lubbock, TX; a 214-unit garden style multifamily community built in 2013 and located in Midland, TX; and a 184-unit garden style multifamily community built in 2004 also located in Lubbock, TX. Lone Star acquired the properties in 2022 and since that time has worked to implement disciplined asset management strategies, focused on targeted operational and physical improvements to the properties designed to strengthen occupancy and improve the overall resident experience. “We saw an opportunity in these assets to focus on providing better services, amenities and an overall higher-quality li
Aptiv and Robust.AI to Co-Develop AI-Powered Collaborative Robots10.11.2025 14:00:00 CET | Press release
Combined Technologies Will Propel Next-Generation Cobots Across Multiple Industries Aptiv PLC (NYSE: APTV), a global technology company focused on enabling a safer, greener, and more connected future, and Robust.AI, a leader in AI-driven industrial automation, today announced a strategic cooperation to co-develop AI-powered collaborative robots (cobots). This partnership combines Aptiv’s industry-leading portfolio, including Wind River platforms and tools—with Robust.AI’s robotics expertise and human-centered design to accelerate innovation in warehouse and industrial automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110931648/en/ Aptiv and Robust.AI partner to co-develop AI-powered collaborative robots (cobots), integrating Aptiv’s industry-leading portfolio—including the PULSE sensor—with Robust.AI’s robotics expertise and human-centered design. “Aptiv, together with our strategic partners, is enabling the futu
Hopewind Selects Wolfspeed to Power the Future of Wind Energy with Advanced Silicon Carbide Technology10.11.2025 14:00:00 CET | Press release
Collaboration enables Hopewind to launch the wind power industry’s first all-silicon carbide power cabinet Wolfspeed, Inc. (NYSE: WOLF), a global leader in innovative silicon carbide power solutions, today announced a collaborationwith Hopewind, a global innovator in renewable energy solutions. Together, the two companies will advance the development of the next generation of wind power solutions by integrating Wolfspeed’s cutting-edge 2.3kV LM Pack Module into Hopewind’s advanced highly modular and lightweight 950Vac Wind Power Converter. Hopewind, one of the largest wind power converter suppliers in China, has taken a novel approach to their wind power solution: This product utilizes silicon carbide devices and high-reliability packaging technology to achieve a up to 38% increase in power density and a high switching frequency of up to 6kHz, significantly increasing efficiency and reliability. The collaborationbetween Wolfspeed and Hopewind is expected to accelerate the development o
Venture Global Announces Long-term Sales and Purchase Agreement With Naturgy of Spain10.11.2025 13:00:00 CET | Press release
Venture Global’s second long-term contract with a Spanish company5.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE:VG) and Naturgy announced the execution of a new long-term Sales and Purchase Agreement (SPA) for the purchase of 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global for twenty years beginning in 2030. The agreement represents Spain’s first long-term contract for American LNG since Venture Global’s first contract in 2018. To date, Venture Global has supplied Spain with 35 cargoes from its Calcasieu Pass and Plaquemines facilities. “Venture Global is honored to expand our long-term partnership with Spain through this new agreement with Naturgy, a leading global LNG company,” said Mike Sabel, CEO of Venture Global. “This contract will positively impact the U.S. balance of trade with Spain and enhance energy security across the region. Our unmatched speed and execution have made Venture
71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis10.11.2025 13:00:00 CET | Press release
Geopolitical turbulence is pushing AI to the forefront of the innovation agenda, but many supply chains are not ready According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact. Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and just 22% have a defined AI strategy, and those with one are more than three times as likely to see measurable ROI. Moreover, while business leaders tend to underestimate the new risks and complexities that AI may introduce, staff are more focused on the practical realities with the effort, change management, and technical challenges involved in turning AI ambition into everyday impact. “Disruption is no longer cyclic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom